Literature DB >> 1679343

Vanadate inhibits agonist binding to D2 dopamine receptor.

Z Elazar1, S Fuchs.   

Abstract

Orthovanadate (in the micromolar range) inhibits the high-affinity binding of the D2 dopamine receptor to specific agonists (apomorphine and N-propylnorapomorphine), while it does not affect the binding to D2 antagonists (spiperone and haloperidol). These effects of vanadate resemble those observed with guanine nucleotides or their analogs. However, in contrast to the guanine nucleotides, vanadate does not induce dissociation of the D2 dopamine receptor from its related G proteins, suggesting that vanadate and guanine nucleotides may exert their effect on the D2 dopamine receptor via different mechanisms. The effect of vanadate on agonist binding was shown to be ATP dependent and correlated with increased protein phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679343     DOI: 10.1007/bf02896843

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  27 in total

1.  Vanadate--a new tool for biologists.

Authors:  T J Simons
Journal:  Nature       Date:  1979-10-04       Impact factor: 49.962

2.  The interaction between D-2 dopamine receptors and GTP-binding proteins.

Authors:  K Ohara; K Haga; G Berstein; T Haga; A Ichiyama; K Ohara
Journal:  Mol Pharmacol       Date:  1988-03       Impact factor: 4.436

Review 3.  Phosphorylation of cell surface receptors: a mechanism for regulating signal transduction pathways.

Authors:  D R Sibley; J L Benovic; M G Caron; R J Lefkowitz
Journal:  Endocr Rev       Date:  1988-02       Impact factor: 19.871

4.  Identification, purification, and characterization of phosphotyrosine-specific protein phosphatases from cultured chicken embryo fibroblasts.

Authors:  R L Nelson; P E Branton
Journal:  Mol Cell Biol       Date:  1984-06       Impact factor: 4.272

5.  Vanadate, epidermal growth factor and the stimulation of DNA synthesis.

Authors:  G Carpenter
Journal:  Biochem Biophys Res Commun       Date:  1981-10-30       Impact factor: 3.575

6.  Angiotensin II and dopamine modulate both cAMP and inositol phosphate productions in anterior pituitary cells. Involvement in prolactin secretion.

Authors:  A Enjalbert; F Sladeczek; G Guillon; P Bertrand; C Shu; J Epelbaum; A Garcia-Sainz; S Jard; C Lombard; C Kordon
Journal:  J Biol Chem       Date:  1986-03-25       Impact factor: 5.157

7.  Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process.

Authors:  D M Cooper; C M Bier-Laning; M K Halford; M K Ahlijanian; N R Zahniser
Journal:  Mol Pharmacol       Date:  1986-02       Impact factor: 4.436

8.  Specificity of receptor-G protein interactions. Discrimination of Gi subtypes by the D2 dopamine receptor in a reconstituted system.

Authors:  S E Senogles; A M Spiegel; E Padrell; R Iyengar; M G Caron
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

9.  Dopamine inhibits 32P incorporation into phosphatidylinositol in the anterior pituitary gland of the rat.

Authors:  P L Canonico; C A Valdenegro; R M Macleod
Journal:  Endocrinology       Date:  1982-07       Impact factor: 4.736

10.  Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Authors:  A Enjalbert; J Bockaert
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.